Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review

被引:8
作者
Kanamori, Kohei [1 ]
Yamagata, Yukinori [1 ]
Honma, Yoshitaka [2 ,3 ]
Date, Keiichi [1 ]
Wada, Takeyuki [1 ]
Hayashi, Tsutomu [1 ]
Otsuki, Sho [1 ]
Sekine, Shigeki [4 ]
Yoshikawa, Takaki [1 ]
Katai, Hitoshi [1 ]
Nishida, Toshiro [1 ]
机构
[1] Natl Canc Ctr, Gastr Surg Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Head & Neck Med Oncol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[4] Natl Canc Ctr, Div Pathol & Clin Labs, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
关键词
Extra-gastrointestinal stromal tumor; Omentum; Platelet-derived growth factor receptor alpha; ADJUVANT IMATINIB; GREATER OMENTUM; C-KIT; RISK; FEATURES;
D O I
10.1186/s12957-020-01961-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Gastrointestinal stromal tumors (GIST) arising from sites other than the gastrointestinal (GI) tract, termed extra-gastrointestinal stromal tumors (EGIST), are rare. Among EGIST, those with platelet-derived growth factor receptor alpha (PDGFRA) mutations are even rarer, with only a few cases reported. About 80% of GIST hasKITmutations, and 10% of GIST havePDGFRAmutations, which commonly affect the TK2 domain (exon 18). Among the exon 18 mutations, theD842Vsubstitution is limited to gastric GIST. In EGIST, the degree ofKITandPDGFRAmutations varies on where the location of the tumor is, and it is suggested that omental EGIST is similar to gastric GIST. Adjuvant imatinib therapy is recommended for high-risk GIST; however, it is known that imatinib is less effective against GIST with aPDGFRA D842Vmutation. Case presentation A 75-year-old man was referred to our hospital with an extrinsic tumor of the lesser curvature of the gastric body. Intraoperative findings showed a tumor located outside of the lesser omentum with no connection between the tumor and the gastric wall. The tumor was subsequently resected. Pathological examination indicated a GIST arising in the lesser omentum measuring 70 mm in its longer dimension. Because the tumor had a PDGFRA mutation (D842V substitution), imatinib was suspected to lack efficacy to the tumor. Thus, although the tumor was considered clinically to have a high risk of recurrence, adjuvant imatinib therapy was not indicated. The patient has been free of recurrence for 29 months since the surgery. Conclusion We described a case of EGIST with a PDGFRA mutation arising in the lesser omentum. And we reviewed 57 cases of omental EGIST and showed that the clinicopathological characteristics and mutation status in omental EGIST were very similar to gastric GIST. In particular,PDGFAR D842Vmutation rate in omental EGIST seemed as high as that in gastric GIST. These results suggested that omental EGIST is strongly related to gastric GIST, so the behavior of omental EGIST might be akin to gastric GIST. However, further studies are required to determine the prognosis and the necessity of adjuvant therapy for EGIST with aPDGFRAmutation.
引用
收藏
页数:7
相关论文
共 47 条
[1]   Gastrointestinal stromal tumours:: a regular origin in the muscularis propria, but an extremely diverse gross presentation -: A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours [J].
Agaimy, Abbas ;
Wuensch, Peter H. .
LANGENBECKS ARCHIVES OF SURGERY, 2006, 391 (04) :322-329
[2]   Current clinical management of gastrointestinal stromal tumor [J].
Akahoshi, Kazuya ;
Oya, Masafumi ;
Koga, Tadashi ;
Shiratsuchi, Yuki .
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (26) :2806-2817
[3]   Clinicopathological and Molecular Factors, Risk Factors, Treatment Outcomes and Risk of Recurrence in Mesenteric and Retroperitoneal Extragastrointestinal Stromal Tumors [J].
Apostolou, Konstantinos G. ;
Schizas, Dimitrios ;
Vavouraki, Eleni ;
Michalinos, Adamantios ;
Tsilimigras, Diamantis I. ;
Garmpis, Nikolaos ;
Damaskos, Christos ;
Papalampros, Alexandros ;
Liakakos, Theodore .
ANTICANCER RESEARCH, 2018, 38 (04) :1903-1909
[4]   Gastrointestinal Stromal Tumors Molecular Markers and Genetic Subtypes [J].
Barnett, Christine M. ;
Corless, Christopher L. ;
Heinrich, Michael C. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (05) :871-888
[5]   Stromal tumor of the lesser omentum : a case report [J].
Behammane, Hossam ;
Aggouri, Younes ;
Oussaid, Morad ;
Laalim, Said Ait ;
Toughrai, Imane ;
Ibn majdoub, Karim ;
Mazaz, Khalid .
PAN AFRICAN MEDICAL JOURNAL, 2014, 17 :236
[6]   An omental mass: any hypothesis? [J].
Caricato, M ;
Ausania, F ;
Valeri, S ;
Rabitti, C ;
Tonini, G ;
Coppola, R .
COLORECTAL DISEASE, 2005, 7 (04) :417-418
[7]   Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era [J].
Cassier, Philippe A. ;
Fumagalli, Elena ;
Rutkowski, Piotr ;
Schoeffski, Patrick ;
Van Glabbeke, Martine ;
Debiec-Rychter, Maria ;
Emile, Jean-Francois ;
Duffaud, Florence ;
Martin-Broto, Javier ;
Landi, Bruno ;
Adenis, Antoine ;
Bertucci, Francois ;
Bompas, Emmanuelle ;
Bouche, Olivier ;
Leyvraz, Serge ;
Judson, Ian ;
Verweij, Jaap ;
Casali, Paolo ;
Blay, Jean-Yves ;
Hohenberger, Peter .
CLINICAL CANCER RESEARCH, 2012, 18 (16) :4458-4464
[8]   A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature [J].
Castillo-Sang, Mario ;
Mancho, Salim ;
Tsang, Albert W. ;
Gociman, Barbu ;
Almaroof, Babatunde ;
Ahmed, Mohammed Y. .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2008, 6 (1)
[9]   PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib [J].
Corless, CL ;
Schroeder, A ;
Griffith, D ;
Town, A ;
McGreevey, L ;
Harrell, P ;
Shiraga, S ;
Bainbridge, T ;
Morich, J ;
Heinrich, MC .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5357-5364
[10]   Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group [J].
Debiec-Rychter, M ;
Dumez, H ;
Judson, I ;
Wasag, B ;
Verweij, J ;
Brown, M ;
Dimitrijevic, S ;
Sciot, R ;
Stul, M ;
Vranck, H ;
Scurr, M ;
Hagemeijer, A ;
Van Glabbeke, M ;
van Oosterom, AT .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (05) :689-695